drugset / Trial / NCT03233633

Marijuana in Combination With Opioids in Palliative and Hospice Patients

NCT03233633

Phase 1 Completed 66 enrolled The Connecticut Hospice Inc.
NaSingle-groupOpen-labelSupportive care

Summary

Study Objectives: Primary reduction of pain and reduction in overall opioid utilization. Secondary improvement in overall patient well being, weight stabilization with increased appetite, improved oxygen saturation, improvement or prevention of nausea and vomiting. Study Rationale: To determine optimum use and dosing of medical marijuana (CBD:THC) for pain and symptom management. Study Population: This study specifically will enroll cancer and non-cancer patients as a primary diagnosis suffering from pain and having a terminal illness (defined as having less than 6 months to live) requiring end of life care.

Timeline

Start
2017-05-10
Primary completion
2022-08-05
Completion
2022-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified Oral

Indications

No indication recorded.